news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Meijing AI News,Guohai Securities released a research report on August 17, giving Jianmin Group (600976.SH) a buy rating. The reasons for the rating mainly include: 1) Marketing reform has been launched, optimizing the assessment method, and improving sales and operation capabilities; 2) In the first half of 2024, brand building and R&D investment will be increased, and the pre-payment of expenses will affect short-term profits, increase long-term brand influence and product reserves; 3) Prescription drugs have been approved for marketing in recent years, and the R&D product pipeline is rich; 4) In vitro cultivation of bezoar maintains stable growth. Risk warning: product sales are lower than expected; the price of Chinese medicine raw materials has risen sharply; product competition has intensified; pharmaceutical commercial income has fluctuated; macroeconomic development is lower than expected; pharmaceutical policy risks, etc.

AI comment: Jianmin Group has received attention from 2 brokerage research reports in the past month, with 1 purchased and 1 increased holdings.

Every headline (nbdtoutiao)——

(Reporter Wang Xiaobo)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. You will be responsible for your own risks if you act accordingly.

Daily Economic News